This content has been archived. It may no longer be relevant
MSC seeks out input of people with MS on treatment
The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies for relapsing-remitting and primary progressive forms of multiple sclerosis. Insurers may use ICER recommendations to develop or change their approved drug lists, which could potentially improve or restrict access to MS medications for people living with MS. To ensure that people living with MS have direct input into their analysis of the use and effectiveness of disease-modifying therapies, the MS Coalition contacted ICER.
As a result of our discussions, a joint survey has been developed to gain valuable patient input into the use of these drugs.
If you are a person diagnosed with MS, whether or not you are taking a disease-modifying treatment, your experience matters. In just five to ten minutes, you can provide valuable input by completing this short, anonymous survey. Your participation is vital to this effort to determine whether we can help improve your access to and satisfaction with MS drug therapy.
Please let us know how you feel about disease-modifying medication(s) for MS by completing this survey, using the link below. The survey will be active from August 31st through September 14th.
